Double-Targeted cell therapy trial launches for tough leukemia cases
NCT ID NCT07336875
Summary
This early-phase study is testing a new type of cell therapy for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to recognize and attack two specific markers found on leukemia cells. Researchers will give a single infusion of these modified cells to up to 30 participants and monitor their safety and how well the leukemia responds over three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.